Anebulo Pharmaceuticals reported net income of -$2.00M for the quarter ended Dec 2025. This income statement covers 23 quarters of results from Jun 2020 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 12.98M | 13.61M | 23.34M | 23.34M | 23.34M | 23.34M | 25.63M | 25.63M | 25.63M | 25.63M | 25.63M | 25.93M | 25.93M | 25.93M | 25.93M | 27.42M | 41.08M | 33.82M | 41.08M | 41.08M | |||
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 0.27M | 1.81M | 0.72M | 0.21M | 0.92M | 1.12M | 1.22M | 1.87M | 1.09M | 1.42M | 1.27M | 1.06M | 0.75M | 0.47M | 1.31M | 1.22M | 0.64M | 1.13M | 0.81M | 1.16M | |||
| Selling, General & AdministrativeSG&A | 0.28M | 0.68M | 0.84M | 0.86M | 0.96M | 1.21M | 1.39M | 1.94M | 1.77M | 1.08M | 1.27M | 1.70M | 0.92M | 0.87M | 1.10M | 1.37M | 1.25M | 1.20M | 1.45M | 1.46M | |||
| Restructuring CostsRestructuring | 0.02M | ||||||||||||||||||||||
| Other Operating ExpensesOther Opex | -0.02M | ||||||||||||||||||||||
| Operating ExpensesOpex | 0.55M | 2.48M | 1.55M | 1.07M | 1.88M | 2.33M | 2.61M | 3.81M | 2.86M | 2.49M | 2.54M | 2.76M | 1.66M | 1.34M | 2.41M | 2.59M | 1.89M | 2.33M | 2.26M | 2.62M | |||
| Operating IncomeOp. Inc | -0.55M | -2.48M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.81M | -2.86M | -2.49M | -2.54M | -2.76M | -1.66M | -1.34M | -2.41M | -2.59M | -1.89M | -2.33M | -2.26M | -2.62M | |||
| EBIT | -0.55M | -2.48M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.81M | -2.86M | -2.49M | -2.54M | -2.76M | -1.66M | -1.34M | -2.41M | -2.59M | -1.89M | -2.33M | -2.26M | -2.62M | |||
| Non-operating items | |||||||||||||||||||||||
| Non Operating Interest Expenses | 0.00M | 0.00M | 0.03M | 0.06M | 0.11M | 0.10M | 0.10M | 0.25M | 0.04M | 0.02M | 0.02M | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.08M | 6.00 | 0.06M | 0.08M | 0.07M | 0.05M | 0.03M | 0.01M | 0.10M | 0.12M | 0.11M | 0.09M | ||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.00M | -0.00M | 0.00M | -0.00M | -212.00 | -0.02M | -0.01M | -0.00M | 0.01M | -594.00 | 0.00M | -124.00 | -283.00 | 47.00 | -528.00 | -431.00 | -96.00 | -34.00 | |||||
| Non Operating IncomeNon Op. Inc. | -0.00M | -26.63M | 0.00M | 0.00M | 0.00M | -212.00 | -0.01M | 0.07M | -0.00M | 0.06M | 0.04M | 0.01M | -0.01M | 0.21M | 0.13M | 0.22M | 0.19M | 0.10M | 0.62M | ||||
| Net income details | |||||||||||||||||||||||
| EBT | -0.56M | -2.47M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.80M | -2.78M | -2.49M | -2.49M | -2.72M | -1.66M | -1.40M | -2.49M | -2.68M | -2.04M | -2.24M | -2.17M | -2.55M | |||
| Profit After TaxPAT | -0.56M | -29.11M | -1.55M | -1.07M | -1.88M | -2.32M | -2.61M | -3.83M | -2.80M | -2.50M | -2.48M | -2.72M | -1.65M | -1.35M | -2.20M | -2.46M | -1.68M | -2.16M | -2.16M | -2.00M | |||
| Income from Continuing OperationsIncome (Continuing) | -0.56M | -2.47M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.80M | -2.78M | -2.49M | -2.49M | -2.72M | -1.66M | -1.40M | -2.49M | -2.68M | -2.04M | -2.24M | -2.17M | -2.55M | |||
| Consolidated Net IncomeConsol Net Inc. | -0.56M | -2.47M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.80M | -2.78M | -2.49M | -2.49M | -2.72M | -1.66M | -1.40M | -2.49M | -2.68M | -2.04M | -2.24M | -2.17M | -2.55M | |||
| Income towards Parent CompanyParent Net Inc | -0.56M | -2.47M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.80M | -2.78M | -2.49M | -2.49M | -2.72M | -1.66M | -1.40M | -2.49M | -2.68M | -2.04M | -2.24M | -2.17M | -2.55M | |||
| Preferred Dividend PaymentsPref Dividends | 8.21M | ||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -8.76M | -29.11M | -1.55M | -1.07M | -1.88M | -2.32M | -2.61M | -3.80M | -2.78M | -2.49M | -2.49M | -2.72M | -1.66M | -1.40M | -2.49M | -2.68M | -2.04M | -2.24M | -2.17M | -2.55M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -0.68 | -2.14 | -0.07 | -0.05 | -0.08 | -0.10 | -0.11 | -0.15 | -0.11 | -0.10 | -0.10 | -0.11 | -0.06 | -0.05 | -0.10 | -0.10 | -0.05 | -0.07 | -0.05 | -0.06 | |||
| EPS (Diluted) | -0.10 | -0.11 | -0.15 | -0.11 | -0.10 | -0.10 | -0.11 | -0.06 | -0.05 | -0.10 | -0.10 | -0.05 | -0.07 | -0.05 | -0.06 | ||||||||
| Shares Outstanding | 12.98M | 13.61M | 23.34M | 23.34M | 23.34M | 23.34M | 23.42M | 25.63M | 25.63M | 25.07M | 25.63M | 25.79M | 25.93M | 25.82M | 25.93M | 27.42M | 41.08M | 33.82M | 41.08M | 41.08M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 23.34M | 23.42M | 25.63M | 25.63M | 25.07M | 25.63M | 25.79M | 25.93M | 25.82M | 25.93M | 27.42M | 41.08M | 33.82M | 41.08M | 41.08M | ||||||||
| EBITDA | -0.55M | -2.48M | -1.55M | -1.07M | -1.88M | -2.33M | -2.61M | -3.81M | -2.86M | -2.49M | -2.54M | -2.76M | -1.66M | -1.34M | -2.41M | -2.59M | -1.89M | -2.33M | -2.26M | -2.62M | |||
| Interest ExpensesInt Expense | 0.00M | 0.00M | 0.03M | 0.06M | 0.11M | 0.10M | 0.10M | 0.25M | 0.04M | 0.02M | 0.02M |